SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Heldin J.)
 

Sökning: WFRF:(Heldin J.) > Phase I and Pharmac...

Phase I and Pharmacokinetic Evaluation of Intravenous Hyaluronic Acid in Combination with Doxorubicin or 5-Fluorouracil

Rosenthal, Mark A (författare)
Gibbs, Peter (författare)
Brown, Tracey J (författare)
visa fler...
Wong, Shirley (författare)
Uren, Shannon (författare)
Ellis, Andrew (författare)
Li, Lingli (författare)
Uppsala universitet,Ludwiginstitutet för cancerforskning
Heldin, Paraskevi (författare)
Uppsala universitet,Ludwiginstitutet för cancerforskning
Fox, Richard M (författare)
visa färre...
 (creator_code:org_t)
2005-06-03
2005
Engelska.
Ingår i: Chemotherapy. - : S. Karger AG. - 0009-3157 .- 1421-9794. ; 51:2-3, s. 132-141
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND: Pre-clinically, hyaluronan (HA) has been demonstrated to systemically target chemotherapeutic drugs to tumours while ameliorating treatment toxicities. This study is a preliminary clinical investigation to determine if HA could be safely used in combination with 5-fluorouracil (5-FU) and doxorubicin (DOX). METHODS: Thirty patients with metastatic cancer were intravenously administered 500 mg/m2 HA in combination with escalating doses of DOX (30-60 mg/m2) or 5-FU (cumulative dose of 1,350-2,250 mg/m2 per cycle). The effect of pre-administration of 20 mg/m2 of folinic acid on HA/5-FU chemotherapy was also investigated. Patients were randomized to receive either HA/chemotherapy or chemotherapy alone in their first treatment cycle and vice versa for the second cycle. Patients received HA and chemotherapy in all subsequent cycles. RESULTS: Treatment was well tolerated, tumour responses were observed and the co-administration of HA did not alter the pharmacokinetics of clinically relevant doses of 5-FU or DOX. CONCLUSION: High doses of intravenous high-molecular-weight HA can be safely co-administered with clinical doses of chemotherapy without significantly altering the toxicity or pharmacokinetics of the drugs or HA.

Nyckelord

Adjuvants; Immunologic/administration & dosage/adverse effects/*pharmacokinetics
Adult
Aged
Antineoplastic Agents/administration & dosage/adverse effects/*pharmacokinetics
Comparative Study
Dose-Response Relationship; Drug
Doxorubicin/administration & dosage/adverse effects/*pharmacokinetics
Drug Therapy; Combination
Female
Fluorouracil/administration & dosage/adverse effects/*pharmacokinetics
Humans
Hyaluronic Acid/administration & dosage/adverse effects/*pharmacokinetics
Infusions; Intravenous
Leucovorin/pharmacology
Male
Middle Aged
Neoplasm Metastasis
Neoplasms/*drug therapy/pathology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy